Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon PK and Carbamazepine Interaction Study
NCT05581823Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Oct 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tavapadon in Parkinson's disease (PD), sponsored by Cerevel Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at Day 30 and Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Day 30. Started Oct 2022; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05581823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581823.